Articles and Insights About Wearables for Clinical Trials

Company News

Stijn Rogiers Interview About Accelerating Digital Endpoints

Posted by Stijn Rogiers on May 26, 2022

SAS Principal Industry Consultant Stijn Rogiers interviewed VivoSense CEO Dudley Tabakin about the uptake in decentralized clinical trials in response to the ongoing disruptions caused by the Coronavirus pandemic of 2020. As trials move toward decentralization, new processes and strategies are required to effectively collect and analyze patient data in a meaningful and validated way. Here are a few key takeaways from their conversation.

Read More

Pharmaphorum Interview: Accelerating Wearables in Clinical Trials

Posted by pharmaphorum on May 11, 2022

Pharmaphorum interviewed VivoSense CEO Dudley Tabakin and new board members from Xontogeny and Debiopharm to discuss how VivoSense’s recent $25M Series A Financing round will help scale up VivoSense® software and accelerate the use of wearable sensors data in clinical trials.

Read More

Digital Health Expert, Rob Wilson, Joins VivoSense Leadership Team

Posted by Dudley Tabakin on April 6, 2022

Vivosense is pleased to announce that Rob Wilson has joined the company as VP of Marketing Strategy. He brings more than 30 years of expertise in strategic planning, finance, and business development for a wide range of companies in digital health, biotechnology, medical technology, and healthcare service industries.

Read More

VivoSense Announces Closing of $25M Series A Financing

Posted by Dudley Tabakin on March 30, 2022

Proceeds to accelerate the collection and use of wearable sensor data in clinical trials along with the development of novel digital biomarkers.

Funding round co-led by the Perceptive Xontogeny Venture (PXV) Fund and Switzerland-based Debiopharm Innovation Fund.

NEWPORT BEACH, Calif. – March 30, 2022-- VivoSense, Inc., (“VivoSense”) an agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor data, today announced the close of a $25 Million Series A financing round. The financing will accelerate the development of novel digital biomarkers and improve digital clinical outcome assessments (COAs). VivoSense will also use this financing to expand and refine its informatics platform for data analysis from wearable and connected technologies to deliver validated digital COAs for life science research.

Read More

VivoSense Awarded NIH/NCI Grant to Aid in Cancer Research

Posted by Dudley Tabakin on October 15, 2020

VivoSense, Inc. is proud to announce that we have been awarded an NIH/NCI Phase 1 contract to develop software enabling data integration from wearable sensors for cancer patients. The contract will result in the development of the VivoSense Cancer Health Informatics Platform as the leading wearable sensor agnostic cloud platform for cancer research and clinical care.

Read More

RSRT Partners with VivoSense to Develop Digital Biomarkers

Posted by Dudley Tabakin on March 17, 2020


Image Source: RSRT, Randol Family

VivoSense announces a series of new collaborations with the Rett Syndrome Research Trust (RSRT) to develop digital biomarkers that better assess the symptoms of Rett syndrome, focusing on autonomic dysfunction and other difficult-to-evaluate symptoms. The goal in developing these digital biomarkers is to better quantify and understand symptom impact on everyday life and to assess new treatments accurately.

Read More

ActiGraph Partners with VivoSense to Enhance Secure Access to Regulated Sensor Data from Patients in Pharmaceutical Clinical Trials

Posted by Dudley Tabakin on May 22, 2019

ActiGraph, the leading provider of medical-grade wearable activity and sleep monitoring solutions, has announced a new partnership with data analytics specialist VivoSense. The partnership will enhance the ability of both companies to deliver sponsor access to secure, regulated, analyzed, and contextualized sensor data from patients participating in pharmaceutical clinical trials. VivoSense is a regulatory compliant, cloud based platform for the analysis of wearable sensor data. VivoSense with VivoCapture provides pharmaceutical sponsors with secure access to contextualized sensor data, metadata, analyzed, and raw signals. The platform makes use of Azure authentication and authorization, computing, and storage in a regulated sensor data warehouse.

Read More

VivoSense Clinical Trials Services now offered in the Microsoft Azure Marketplace

Posted by Dudley Tabakin on April 2, 2019

Vivonoetics, a Microsoft Cloud Partner, now offers VivoSense in both the Azure Marketplace and AppSource. VivoSense is a regulatory compliant, cloud based platform for the analysis of wearable sensor data. VivoSense with VivoCapture provides pharmaceutical sponsors with secure access to contextualized sensor data, metadata, analyzed and raw signals. The platform makes use of Azure authentication and authorization, computing, and storage in a regulated sensor data warehouse.

Read More

Indie Health Partners with VivoSense to Provide Advanced Insights in Chronic Disease Management and Pharmaceutical Clinical Trials

Posted by Dudley Tabakin on March 5, 2019

San Diego, CA, March 5, 2019 — Biometric sensor provider Indie Health announces its partnership with data analytics specialist VivoSense, to accelerate the delivery of actionable insights and accurate monitoring of patients’ health status. Combining VivoSense software with Indie Health sensor data ensures complete data integrity and structures it within a secure, regulatory-compliant and auditable environment.

Read More

VivoSense (Vivonoetics, Inc.) Announces its Partnership with Cardiac Insight, Inc.

Posted by VivoSense Team on November 1, 2018

VivoSense (Vivonoetics, Inc.) is proud to announce its partnership with Cardiac Insight, Inc. to expand the use of its wearable cardiac sensors in regulated pharmaceutical clinical trials and other healthcare research applications. To find out more, read our featured article in Business Wire.

Read More

Subscribe to Email Updates

Stay Connected

Popular